RT Journal Article
SR Electronic
T1 Outcome measurement in functional neurological disorder: a systematic review and recommendations
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 638
OP 649
DO 10.1136/jnnp-2019-322180
VO 91
IS 6
A1 Pick, Susannah
A1 Anderson, David G
A1 Asadi-Pooya, Ali A
A1 Aybek, Selma
A1 Baslet, Gaston
A1 Bloem, Bastiaan R
A1 Bradley-Westguard, Abigail
A1 Brown, Richard J
A1 Carson, Alan J
A1 Chalder, Trudie
A1 Damianova, Maria
A1 David, Anthony S
A1 Edwards, Mark J
A1 Epstein, Steven A
A1 Espay, Alberto J
A1 Garcin, Béatrice
A1 Goldstein, Laura H
A1 Hallett, Mark
A1 Jankovic, Joseph
A1 Joyce, Eileen M
A1 Kanaan, Richard A
A1 Keynejad, Roxanne C
A1 Kozlowska, Kasia
A1 LaFaver, Kathrin
A1 LaFrance, Jr., W Curt
A1 Lang, Anthony E
A1 Lehn, Alex
A1 Lidstone, Sarah
A1 Maurer, Carine W
A1 Mildon, Bridget
A1 Morgante, Francesca
A1 Myers, Lorna
A1 Nicholson, Clare
A1 Nielsen, Glenn
A1 Perez, David L
A1 Popkirov, Stoyan
A1 Reuber, Markus
A1 Rommelfanger, Karen S
A1 Schwingenshuh, Petra
A1 Serranova, Tereza
A1 Shotbolt, Paul
A1 Stebbins, Glenn T
A1 Stone, Jon
A1 Tijssen, Marina AJ
A1 Tinazzi, Michele
A1 Nicholson, Timothy R
YR 2020
UL http://jnnp.bmj.com/content/91/6/638.abstract
AB Objectives We aimed to identify existing outcome measures for functional neurological disorder (FND), to inform the development of recommendations and to guide future research on FND outcomes.Methods A systematic review was conducted to identify existing FND-specific outcome measures and the most common measurement domains and measures in previous treatment studies. Searches of Embase, MEDLINE and PsycINFO were conducted between January 1965 and June 2019. The findings were discussed during two international meetings of the FND-Core Outcome Measures group.Results Five FND-specific measures were identified—three clinician-rated and two patient-rated—but their measurement properties have not been rigorously evaluated. No single measure was identified for use across the range of FND symptoms in adults. Across randomised controlled trials (k=40) and observational treatment studies (k=40), outcome measures most often assessed core FND symptom change. Other domains measured commonly were additional physical and psychological symptoms, life impact (ie, quality of life, disability and general functioning) and health economics/cost–utility (eg, healthcare resource use and quality-adjusted life years).Conclusions There are few well-validated FND-specific outcome measures. Thus, at present, we recommend that existing outcome measures, known to be reliable, valid and responsive in FND or closely related populations, are used to capture key outcome domains. Increased consistency in outcome measurement will facilitate comparison of treatment effects across FND symptom types and treatment modalities. Future work needs to more rigorously validate outcome measures used in this population.